{"count": 2, "results": [{"_id": "33608711", "pmid": 33608711, "pmcid": "PMC8266622", "title": "Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial", "journal": "Schizophr Bull", "authors": ["Sommer IE", "Gangadin SS", "de Witte LD", "Koops S", "van Baal C", "Bahn S", "Drexhage H", "van Haren NEM", "Veling W", "Bruggeman R", "Martens P", "Wiersma S", "Veerman SRT", "Grootens KP", "van Beveren N", "Kahn RS", "Begemann MJH"], "date": "2021-07-08T00:00:00Z", "doi": "10.1093/schbul/sbab010", "meta_date_publication": "2021 Jul 8", "meta_volume": "47", "meta_issue": "4", "meta_pages": "1108-1115", "score": 50272.19, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Augmentation for @SPECIES_9606 @@@Patients@@@ With Early-Phase @<m>DISEASE_Schizophrenia_Spectrum_and_Other_Psychotic_Disorders</m> @DISEASE_MESH:D019967 @@@Schizophrenia-Spectrum Disorders@@@: A Double-Blind, Randomized Placebo-Controlled Trial", "citations": {"NLM": "Sommer IE, Gangadin SS, de Witte LD, Koops S, van Baal C, Bahn S, Drexhage H, van Haren NEM, Veling W, Bruggeman R, Martens P, Wiersma S, Veerman SRT, Grootens KP, van Beveren N, Kahn RS, Begemann MJH. Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial Schizophr Bull. 2021 Jul 8;47(4):1108-1115. PMID: 33608711", "BibTeX": "@article{33608711, title={Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial}, author={Sommer IE and Gangadin SS and de Witte LD and Koops S and van Baal C and Bahn S and Drexhage H and van Haren NEM and Veling W and Bruggeman R and Martens P and Wiersma S and Veerman SRT and Grootens KP and van Beveren N and Kahn RS and Begemann MJH}, journal={Schizophr Bull}, volume={47}, number={4}, pages={1108-1115}}"}}, {"_id": "36405425", "pmid": 36405425, "pmcid": "PMC9668621", "title": "Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial", "journal": "Brain Behav Immun Health", "authors": ["Aichholzer M", "Gangadin SS", "Sommer IEC", "Wijkhuis A", "de Witte LD", "Kahn RS", "Bahn S", "Drexhage HA", "Schiweck C"], "date": "2022-11-08T00:00:00Z", "doi": "10.1016/j.bbih.2022.100551", "meta_date_publication": "2022 Dec", "meta_volume": "26", "meta_issue": "", "meta_pages": "100551", "score": 50264.68, "text_hl": "In our previous analysis of the randomized controlled trial with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Schizophrenia_Spectrum_and_Other_Psychotic_Disorders</m> @DISEASE_MESH:D019967 @@@SSD@@@, the predefined primary outcome, i.e., symptom severity as measured with the PANSS total score at 12 months of treatment, was negative. ", "citations": {"NLM": "Aichholzer M, Gangadin SS, Sommer IEC, Wijkhuis A, de Witte LD, Kahn RS, Bahn S, Drexhage HA, Schiweck C. Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial Brain Behav Immun Health. 2022 Dec;26():100551. PMID: 36405425", "BibTeX": "@article{36405425, title={Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial}, author={Aichholzer M and Gangadin SS and Sommer IEC and Wijkhuis A and de Witte LD and Kahn RS and Bahn S and Drexhage HA and Schiweck C}, journal={Brain Behav Immun Health}, volume={26}, pages={100551}}"}}]}